“IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS”, jmsi, vol. 5, no. 03, pp. 1709–1714, Mar. 2026, doi: 10.55640/.